These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 34904800)

  • 1. Brain-derived neurotrophic factor serum levels following ketamine and esketamine intervention for treatment-resistant depression: secondary analysis from a randomized trial.
    Caliman-Fontes AT; Leal GC; Correia-Melo FS; Paixão CS; Carvalho MS; Jesus-Nunes AP; Vieira F; Magnavita G; Bandeira ID; Mello RP; Beanes G; Silva SS; Echegaray M; Carvalho LP; Machado P; Sampaio AS; Cardoso TA; Kapczinski F; Lacerda ALT; Quarantini LC
    Trends Psychiatry Psychother; 2023; 45():e20210298. PubMed ID: 34904800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of GRIN2B , GRIA1 , and BDNF Polymorphisms on the Therapeutic Action of Ketamine and Esketamine in Treatment-Resistant Depression Patients: Secondary Analysis From a Randomized Clinical Trial.
    Beanes G; Caliman-Fontes AT; Souza-Marques B; Silva HDS; Leal GC; Carneiro BA; Guerreiro-Costa LNF; Figueiredo AV; Figueiredo CAV; Lacerda ALT; Costa RDS; Quarantini LC
    Clin Neuropharmacol; 2022 Nov-Dec 01; 45(6):151-156. PubMed ID: 36093918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatment-resistant depression.
    Jesus-Nunes AP; Leal GC; Correia-Melo FS; Vieira F; Mello RP; Caliman-Fontes AT; Echegaray MVF; Marback RF; Guerreiro-Costa LNF; Souza-Marques B; Santos-Lima C; Souza LS; Bandeira ID; Kapczinski F; Lacerda ALT; Quarantini LC
    Hum Psychopharmacol; 2022 Jul; 37(4):e2836. PubMed ID: 35179810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression.
    Haile CN; Murrough JW; Iosifescu DV; Chang LC; Al Jurdi RK; Foulkes A; Iqbal S; Mahoney JJ; De La Garza R; Charney DS; Newton TF; Mathew SJ
    Int J Neuropsychopharmacol; 2014 Feb; 17(2):331-6. PubMed ID: 24103211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: A randomized, double-blind, non-inferiority study.
    Correia-Melo FS; Leal GC; Vieira F; Jesus-Nunes AP; Mello RP; Magnavita G; Caliman-Fontes AT; Echegaray MVF; Bandeira ID; Silva SS; Cavalcanti DE; Araújo-de-Freitas L; Sarin LM; Tuena MA; Nakahira C; Sampaio AS; Del-Porto JA; Turecki G; Loo C; Lacerda ALT; Quarantini LC
    J Affect Disord; 2020 Mar; 264():527-534. PubMed ID: 31786030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antisuicidal effect, BDNF Val66Met polymorphism, and low-dose ketamine infusion: Reanalysis of adjunctive ketamine study of Taiwanese patients with treatment-resistant depression (AKSTP-TRD).
    Chen MH; Lin WC; Wu HJ; Cheng CM; Li CT; Hong CJ; Tu PC; Bai YM; Tsai SJ; Su TP
    J Affect Disord; 2019 May; 251():162-169. PubMed ID: 30925267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial.
    Dwyer JB; Landeros-Weisenberger A; Johnson JA; Londono Tobon A; Flores JM; Nasir M; Couloures K; Sanacora G; Bloch MH
    Am J Psychiatry; 2021 Apr; 178(4):352-362. PubMed ID: 33653121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
    Popova V; Daly EJ; Trivedi M; Cooper K; Lane R; Lim P; Mazzucco C; Hough D; Thase ME; Shelton RC; Molero P; Vieta E; Bajbouj M; Manji H; Drevets WC; Singh JB
    Am J Psychiatry; 2019 Jun; 176(6):428-438. PubMed ID: 31109201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meaningful Change in Depression Symptoms Assessed with the Patient Health Questionnaire (PHQ-9) and Montgomery-Åsberg Depression Rating Scale (MADRS) Among Patients with Treatment Resistant Depression in Two, Randomized, Double-blind, Active-controlled Trials of Esketamine Nasal Spray Combined With a New Oral Antidepressant.
    Hudgens S; Floden L; Blackowicz M; Jamieson C; Popova V; Fedgchin M; Drevets WC; Cooper K; Lane R; Singh J
    J Affect Disord; 2021 Feb; 281():767-775. PubMed ID: 33261932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study.
    Singh JB; Fedgchin M; Daly E; Xi L; Melman C; De Bruecker G; Tadic A; Sienaert P; Wiegand F; Manji H; Drevets WC; Van Nueten L
    Biol Psychiatry; 2016 Sep; 80(6):424-431. PubMed ID: 26707087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does the intensity of dissociation predict antidepressant effects 24 hours after infusion of racemic ketamine and esketamine in treatment-resistant depression? A secondary analysis from a randomized controlled trial.
    Echegaray MVF; Mello RP; Magnavita GM; Leal GC; Correia-Melo FS; Jesus-Nunes AP; Vieira F; Bandeira ID; Caliman-Fontes AT; Telles M; Guerreiro-Costa LNF; Marback RF; Souza-Marques B; Lins-Silva DH; Santos-Lima C; Cardoso TA; Kapczinski F; Lacerda ALT; Quarantini LC
    Trends Psychiatry Psychother; 2023 Sep; ():. PubMed ID: 37717263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1).
    Fedgchin M; Trivedi M; Daly EJ; Melkote R; Lane R; Lim P; Vitagliano D; Blier P; Fava M; Liebowitz M; Ravindran A; Gaillard R; Ameele HVD; Preskorn S; Manji H; Hough D; Drevets WC; Singh JB
    Int J Neuropsychopharmacol; 2019 Oct; 22(10):616-630. PubMed ID: 31290965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treating bipolar depression with esketamine: Safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment-resistant depression.
    Martinotti G; Dell'Osso B; Di Lorenzo G; Maina G; Bertolino A; Clerici M; Barlati S; Rosso G; Di Nicola M; Marcatili M; d'Andrea G; Cavallotto C; Chiappini S; De Filippis S; Nicolò G; De Fazio P; Andriola I; Zanardi R; Nucifora D; Di Mauro S; Bassetti R; Pettorruso M; McIntyre RS; Sensi SL; di Giannantonio M; Vita A;
    Bipolar Disord; 2023 May; 25(3):233-244. PubMed ID: 36636839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Commentary on Cochrane review: "Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder".
    Borentain S; Desai P; Fu DJ; Nancy Chen L; Lane R; Mathews M; Canuso CM
    J Psychopharmacol; 2023 Aug; 37(8):836-844. PubMed ID: 36218274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
    Dean RL; Hurducas C; Hawton K; Spyridi S; Cowen PJ; Hollingsworth S; Marquardt T; Barnes A; Smith R; McShane R; Turner EH; Cipriani A
    Cochrane Database Syst Rev; 2021 Sep; 9(9):CD011612. PubMed ID: 34510411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Novel, Brief, Fully Automated Intervention to Extend the Antidepressant Effect of a Single Ketamine Infusion: A Randomized Clinical Trial.
    Price RB; Spotts C; Panny B; Griffo A; Degutis M; Cruz N; Bell E; Do-Nguyen K; Wallace ML; Mathew SJ; Howland RH
    Am J Psychiatry; 2022 Dec; 179(12):959-968. PubMed ID: 36128684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist.
    Machado-Vieira R; Yuan P; Brutsche N; DiazGranados N; Luckenbaugh D; Manji HK; Zarate CA
    J Clin Psychiatry; 2009 Dec; 70(12):1662-6. PubMed ID: 19744406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum BDNF as a peripheral biomarker of treatment-resistant depression and the rapid antidepressant response: A comparison of ketamine and ECT.
    Allen AP; Naughton M; Dowling J; Walsh A; Ismail F; Shorten G; Scott L; McLoughlin DM; Cryan JF; Dinan TG; Clarke G
    J Affect Disord; 2015 Nov; 186():306-11. PubMed ID: 26275358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurocognitive aspects of ketamine and esketamine on subjects with treatment-resistant depression: A comparative, randomized and double-blind study.
    Araújo-de-Freitas L; Santos-Lima C; Mendonça-Filho E; Vieira F; França RJAF; Magnavita G; Cardoso TL; Correia-Melo FS; Leal GC; Jesus-Nunes AP; Souza-Marques B; Marback R; Teles M; Echegaray MV; Beanes G; Guerreiro-Costa LNF; Mello RP; Rabanea T; Lucchese AC; Abreu N; Lacerda ALT; Quarantini LC
    Psychiatry Res; 2021 Sep; 303():114058. PubMed ID: 34153630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study.
    Takahashi N; Yamada A; Shiraishi A; Shimizu H; Goto R; Tominaga Y
    BMC Psychiatry; 2021 Oct; 21(1):526. PubMed ID: 34696742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.